Sequence addresses the biological factors that can prevent weight loss.
*Based on a 68-week clinical trial, patients without diabetes but with a BMI of ≥30, or ≥27 lost an average of 15% of their body weight (-33.6 lbs) on 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. Wegovy® is FDA-approved for weight management.
* Your Sequence program includes the cost of labs and non-GLP-1 medications. The cost of GLP-1 medications is subject to insurance coverage. Your Care Team will help you with insurance coverage.
*Statements reference the GLP-1 class of medications
“I actually feel like the medication is working! My appetite has gone down significantly so it’s been great”
“I don’t have the cravings for sweets & I’m not as hungry anymore. I am so excited!”
“YOLO! I have lost 13 lbs since starting the medicine! Thank you!!!”
“I’ve hit my lowest weight in 3 years — I’m finally back in the right direction”
“It completely curbs my appetite and cravings. I’ve lost 5 lbs already. This is the greatest hope I’ve had in a long time.”
“I have lost 30 pounds and reversed prediabetes. All because of this program.”